Understand the source comparison
Best Peptides for Candida Overgrowth: Research vs Marketing Comparison
Beta-defensins (hBD-1, hBD-2, hBD-3) Yes. MIC 2–8 μg/mL against C. albicans Membrane disruption via pore formation Multiple in vitro studies; limited human trials Strongest documented anti-Candida activity but not orally bioavailable as supplements Cathelicidi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Beta-defensins (hBD-1, hBD-2, hBD-3)
- Yes. MIC 2–8 μg/mL against C. albicans
- Membrane disruption via pore formation
- Multiple in vitro studies; limited human trials
- Strongest documented anti-Candida activity but not orally bioavailable as supplements
- Cathelicidin (LL-37)
- Yes. MIC 8–16 μg/mL; biofilm penetration
- Membrane disruption + biofilm matrix degradation
- In vitro validated; observational human data linking vitamin D status to expression levels
- Produced endogenously; upregulated by vitamin D. Not available as direct supplement
- Histatins (histatin-5)
- Yes. MIC 3–7 μg/mL oral Candida
- Active transport into cells + mitochondrial ROS induction
- In vitro confirmed; clinical validation in Sjögren's syndrome populations
- Saliva-specific; reduced in dry mouth conditions. No supplemental form exists
- Thymosin alpha-1
- No direct activity
- T-cell modulation; Th1 cytokine upregulation
- Phase 2 trials as adjunct in invasive candidiasis; modest benefit
- Supports immune function indirectly. Does not kill Candida
- Thymalin
- Neutrophil chemotaxis enhancement
- Limited Eastern European studies from 1990s; no modern RCTs
- Theoretical immune support; no direct antifungal evidence
- KPV tripeptide
- Anti-inflammatory signaling in gut epithelium
- Small pilot studies in IBD; no Candida-specific trials
- May reduce gut inflammation that favors fungal growth. Indirect mechanism only